BIOMAT Database Logo BIOMAT Database Logo

Serum levels of p53 and cytochrome c in subjects with type 2 diabetes and impaired glucose tolerance. 2009

Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Istanbul University, Cerrahpasa Medical Faculty, Department of Biochemistry. stare63@yahoo.com

OBJECTIVE To examine apoptotic markers in serum of subjects with diabetes and impaired glucose tolerance (IGT). Serum levels of p53 and cytochrome c, regulator molecules for apoptosis, were measured in subjects with type 2 diabetes, subjects with IGT and healthy controls. METHODS Forty one subjects with type 2 diabetes, 27 with IGT and 27 healthy volunteers were included in the study. Serum level of cytochrome c and p53 were measured with competitive ELISA. RESULTS Serum levels of p53 were lower in the group of subjects with type 2 diabetes (085+/-0.39 U/ml) than in controls (1.09+/-0.49 U/ml) (P < 0.05) and in the subjects with IGT (0.98+/-0.37 U/ml) (P < 0.05). There was no significant difference between the group with IGT and controls. Also, there was no difference for serum level of cytochrome c among the groups. In the group of subjects with type 2 diabetes, serum level of cytochrome c was mildly correlated with HbA1c (r:0.39, P < 0.05). CONCLUSIONS The present study shows that the serum level of p53 is lower in the patients with type 2 diabetes than in controls or in subjects with IGT. No difference was seen among the the groups for the serum level of cytochrome c.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Serum lipid levels in subjects with impaired glucose tolerance.
May 1988, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome.
January 2020, Endokrynologia Polska,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Levels of serum sialic acid and thiobarbituric acid reactive substances in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
January 2007, Journal of clinical laboratory analysis,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
[Type 2 diabetes and impaired glucose tolerance].
February 2013, Nihon rinsho. Japanese journal of clinical medicine,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes.
October 2011, Clinical endocrinology,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance.
June 2020, Endocrinology and metabolism (Seoul, Korea),
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
[Significance of insulin measurement in subjects with impaired glucose tolerance or type 2 diabetes].
February 2005, Nihon rinsho. Japanese journal of clinical medicine,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Skin capillary density in subjects with impaired glucose tolerance and patients with type 2 diabetes.
February 1996, Diabetic medicine : a journal of the British Diabetic Association,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
January 2009, Annals of medicine,
Yildiz Dincer, and Solen Himmetoglu, and Serap Yalin, and Taner Damci, and Hasan Ilkova, and Tulay Akcay
Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus.
June 2012, Clinical endocrinology,
Copied contents to your clipboard!